LONDON, July 6, 2026, 19:04 BST
- Haleon slipped 1.6% at the close. The stock trailed the FTSE 100, which lost 0.3%.
- Volume came in around half the 50-day average. Light action for a defensive stock.
- The company reports it had about £70 million in 2026 buyback capacity remaining as of June 18, ahead of later purchases.
- Forecasts continue to expect faster growth after the slow first quarter.
Haleon PLC LON:HLN dropped Monday in light volume, with the Sensodyne and Panadol owner now looking at reduced share-buyback capacity ahead of half-year results on July 30.
The stock fell 1.59% to £3.59. The FTSE 100 (INDEXFTSE:UKX) dropped 0.26% to end at 10,651.77. Haleon closed 13.84% under its Feb. 18 52-week high of £4.16. Trading volume reached 12.6 million shares, well below the 50-day average of 25.4 million, MarketWatch data showed.
The trade wasn’t big, but that’s the point. Haleon has been in the market buying shares back through 2026, and its latest aide memoire put about 86% of its £500 million buyback done as of June 18. With Monday’s price at £3.59, the £70 million still left on the program would take up around 19.5 million shares—about one and a half times what traded on Monday, before any more buys.
Haleon set out its £500 million 2026 buyback plan back in February, launching the on-market repurchase in March. According to its buyback page, the company updates daily transaction details once a week if it bought shares during the previous week.
| Market gauge | Latest figure | Read-through |
|---|---|---|
| Monday share move | -1.59% to about 359p | Trailed FTSE 100 by roughly 1.3 points |
| Monday volume | 12.6 mln shares | That’s half the 50-day average |
| 52-week high gap | -13.84% from £4.16 | Stock is still far under its February top |
| Implied buyback balance at June 18 | About £70 mln | Translates to around 19.5 mln shares at Monday’s price |
The question now is if the company can pull off the full-year growth that’s still in forecasts after a soft first quarter. Haleon posted 2.2% organic revenue growth for Q1. Prices were up 2.4% while volume slipped 0.2%. A weak cold and flu season knocked about 130 basis points off growth, the company said.
Chief Executive Brian McNamara told investors in April that Haleon saw “North America returning to growth” and backed growth “to accelerate across the balance of the year.” The 2026 outlook was left unchanged, calling for 3% to 5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency. Haleon Corporate
Category data shows the gap. Oral Health rose 8.3% organically in Q1. But Respiratory Health dropped 3.4%, Pain Relief slipped 0.3%, and Digestive Health was down 0.4%. In North America, the company’s biggest region, revenue grew just 1.0% in Q1.
| Operating measure | Q1 2026 actual | FY 2026 forecast / guide | FY 2027 forecast |
|---|---|---|---|
| Group organic growth | 2.2% | 3.7% consensus, company sees 3%-5% | 4.6% consensus |
| Group revenue | £2.857 bln | £11.394 bln consensus | £11.899 bln consensus |
| Adjusted EBIT | not given in Q1 | £2.688 bln consensus | £2.871 bln consensus |
| Adjusted EPS | not given in Q1 | 20.6p consensus | 22.7p consensus |
| Dividend per share | not in Q1 | 7.9p consensus | 8.8p consensus |
Vuma estimates in the consensus table come from Haleon, published April 20. Haleon says it doesn’t verify or endorse the data.
Analysts are still pointing higher on price targets. LSEG numbers on Investors Chronicle show 14 analysts with a 12-month median target of 435p, topping out at 512p, with the lowest at 325p. That compares to the 358.5p quoted share price, so the median target points to around 21% upside, while the low end would mean about 9% down.
| Share-price forecast | Pence | Implied move vs 358.5p |
|---|---|---|
| Lowest estimate | 325p | -9.3% |
| Median estimate | 435p | +21.3% |
| Highest estimate | 512p | +42.8% |
That sets up a tight picture for July 30. The buyback cut the share count, but the stock now leans more on a North America volume rebound, Oral Health staying strong, and Respiratory not holding back results. In its H1 aide memoire, the company said weighted average diluted shares for H1 2026 should be around 8.9 billion.
